非抗生素辅助剂可以改善幽门螺杆菌感染的控制。我们的目的是强调姜黄素在控制幽门螺杆菌感染方面的益处。我们使用关键词搜索讨论了大部分自 2020 年以来出版的英文出版物。姜黄素是姜黄中的主要生物活性物质。姜黄素通过剂量和菌株依赖性活性抑制幽门螺杆菌生长、脲酶活性、三个 cag 基因和生物膜。姜黄素还表现出多种抗癌活性，如诱导细胞凋亡、抗炎和抗血管生成作用、上调 caspase-3、增强 Bax 蛋白、激活 p53 基因和化疗增敏。在三项伊朗研究中，该药物作为三联疗法的补充，提高了幽门螺杆菌根除的成功率。脂质体制剂、脂质缀合物、电喷雾封装和与蛋白质的纳米复合物提高了生物利用度。该药物在每天 0.5->4 克的剂量下是安全的，最常见的不良反应（16% 的使用者）是胃肠道不适。值得注意的是，姜黄素对肠道微生物群有积极影响并抑制艰难梭菌。先前的报告显示姜黄素对幽门螺杆菌生长有抑制作用。姜黄素可能成为治疗幽门螺杆菌感染的添加剂、控制胃癌的辅助剂以及有益于肠道微生物群的药物。需要进一步检查以确定其最佳剂量、与抗生素的协同作用、对各种根除方案的补充以及预防潜力。© 作者 2024。由牛津大学出版社代表应用微生物学国际出版。

Non-antibiotic adjuncts may improve Helicobacter pylori infection control. Our aim was to emphasize curcumin benefits in controlling H. pylori infection. We discussed publications in English mostly published since 2020 using keyword search. Curcumin is the main bioactive substance in turmeric. Curcumin inhibited H. pylori growth, urease activity, three cag genes, and biofilms through dose- and strain-dependent activities. Curcumin also displayed numerous anticancer activities such as apoptosis induction, anti-inflammatory and anti-angiogenic effects, caspase-3 upregulation, Bax protein enhancement, p53 gene activation, and chemosensitization. Supplementing triple regimens, the agent increased H. pylori eradication success in three Iranian studies. Bioavailability was improved by liposomal preparations, lipid conjugates, electrospray-encapsulation, and nano-complexation with proteins. The agent was safe at doses of 0.5->4 g daily, the most common (in 16% of the users) adverse effect being gastrointestinal upset. Notably, curcumin favorably influences the intestinal microbiota and inhibits Clostridioides difficile. Previous reports showed inhibitory effect of curcumin on H pylori growth. Curcumin may become an additive in the therapy of H. pylori infection, an adjunct for gastric cancer control, and an agent beneficial to the intestinal microbiota. Further examination is necessary to determine its optimal dosage, synergy with antibiotics, supplementation to various eradication regimens, and prophylactic potential.© The Author(s) 2024. Published by Oxford University Press on behalf of Applied Microbiology International.